Loading
Thyroid Disorders and Treatments / Liver Disease Diagnosis and Treatment · Journal article
Current Opinion in Nephrology & Hypertension · September 2, 2026
A consensus or society position rather than new primary data.
This review proposes integration of liver disease assessment into cardiovascular-kidney-metabolic (CKM) risk stratification, supported by large cohort evidence that coexistent metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease confer additive mortality risk. Recent regulatory approvals of resmetirom (THR-β agonist) and semaglutide for metabolic dysfunction-associated steatohepatitis, along with efficacy of incretin-based therapies across the spectrum, provide therapeutic options and rationale for early identification of MASLD in high-risk populations using noninvasive fibrosis tools.
Journal article. Patients with coexistent metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD); high-risk populations for early MASLD identification..
Coexistent MASLD and CKD confer additive, stage-dependent mortality risk exceeding that of either condition alone Hepatic fibrosis severity, rather than steatosis, is the dominant prognostic driver Resmetirom received FDA-accelerated approval (March 2024) and European Commission conditional marketing authorization (August 2025) as first licensed MASH-specific therapy
Review does not report effect sizes, hazard ratios, or confidence intervals for mortality risk quantification Coexistent MASLD and CKD confer additive, stage-dependent mortality risk exceeding that of either condition alone
Clinicians should integrate noninvasive liver fibrosis assessment into standard risk stratification for CKD populations and consider newer therapeutics (resmetirom, semaglutide, tirzepatide) that address the expanded cardiovascular-renal-hepatic-metabolic syndrome across multiple organ systems. Early identification of hepatic fibrosis, not steatosis alone, should guide treatment decisions.
A narrative review synthesizing mechanistic, epidemiological, and therapeutic evidence to recommend integration of liver assessment into cardiovascular-kidney-metabolic risk stratification and therapy selection in clinical practice.
Quoted from the source exactly as published.
Clinicians should integrate noninvasive liver fibrosis assessment into standard risk stratification for CKD populations and consider newer therapeutics (resmetirom, semaglutide, tirzepatide) that address the expanded cardiovascular-renal-hepatic-metabolic syndrome across multiple organ systems. Early identification of hepatic fibrosis, not steatosis alone, should guide treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
PURPOSE OF REVIEW: This review examines the mechanistic, epidemiological and therapeutic evidence underpinning liver integration into the cardiovascular-kidney-metabolic (CKM) construct. For the purposes of this review, we use the term cardiovascular-renal-hepatic-metabolic (CRHM) syndrome to denote this expanded framework, acknowledging that consensus nomenclature is yet to be established. RECENT FINDINGS: Large cohort data confirm that coexistent metabolic dysfunction-associated steatotic liver disease (MASLD) and CKD confer additive, stage-dependent mortality risk exceeding that of either condition alone, with hepatic fibrosis severity, rather than steatosis, the dominant prognostic driver. The past 12-18 months have seen significant therapeutic developments spanning the full CRHM spectrum. Resmetirom, a hepato-selective thyroid hormone receptor-β (THR-β) agonist, received FDA-accelerated approval (March 2024) and European Commission conditional marketing authorization (August 2025) as the first licensed metabolic dysfunction-associated steatohepatitis (MASH)-specific therapy; UK approval is pending. Incretin-based therapies demonstrated efficacy across the full CRHM spectrum: semaglutide in diabetic and non-diabetic kidney disease across FLOW, SELECT, and SMART trials; tirzepatide in obesity-related heart failure with preserved ejection fraction (HFpEF) in SUMMIT. Semaglutide additionally received accelerated FDA approval and EU marketing authorization for MASH following the ESSENCE trial; UK approval for this indication is pending. SUMMARY: The integration of the liver into CKM staging now has implications for how clinicians stratify risk and select therapy. Early identification of MASLD in CKD cohorts using validated noninvasive fibrosis tools should be considered standard practice in high-risk populations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.